肝指标对经导管主动脉瓣植入患者临床结局的影响
该研究纳入640例连续TAVR患者,其中11例术前存在慢性肝病,用MELD评分评估肝功能。结果显示慢性肝病组与无肝病组30天死亡率均为9.1%(p=1.00),TAVR后第3天ALT较术前显著升高且白蛋白显著下降。提示肝肝硬化本身并非TAVR禁忌,慢性肝病患者行TAVR可行且结局可接受。
要点
- 慢性肝病TAVR患者30天死亡率9.1%,与无肝病组无差异。
- TAVR后第3天ALT显著升高、白蛋白显著下降。
- 肝硬化本身不应视为TAVR的禁忌证。
核心结论
- 肝硬化本身不视为心脏手术的禁忌证。
- 本研究中肝肝硬化患者行TAVR未观察到更高的30天死亡率,提示TAVR是慢性肝病患者可行且结局可接受的选择。
- 本研究首次评估了TAVR患者的肝脏指标。
研究设计与样本
- 回顾性评估640例连续TAVR患者,其中11例术前存在慢性肝病。
- 采用终末期肝病模型(MELD)评分评估肝功能。
- 主要终点为肝功能障碍患者的30天死亡率,次要终点为TAVR后肝酶变化。
主要发现
- 慢性肝病组平均MELD评分为16.8 ± 6.2(中位数18,范围7至26)。
- 无肝病组30天死亡率为9.1%(57/629),肝病组为9.1%(1/11),p = 1.00。
- 慢性肝病患者术前γ-谷氨酰转肽酶水平显著更高(p < 0.001)。
- TAVR后第3天丙氨酸氨基转移酶较术前显著升高(p < 0.001),同时白蛋白显著下降(p < 0.001)。
临床怎么用
- 对合并慢性肝病的主动脉瓣狭窄患者,TAVR可作为可行选择,但需注意术后肝酶升高和白蛋白下降。
局限性
- 慢性肝病组样本量仅11例,结论需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Liver dysfunction increases death and morbidity after cardiac operations. There are currently no data evaluating liver function in patients undergoing transcatheter aortic valve replacement (TAVR). We aimed therefore to evaluate our TAVR results in regard to liver function. METHODS: A total of 640 consecutive TAVR patients were evaluated. Of those, 11 patients presented with chronic liver disease before TAVR. The Model for End-Stage Liver Disease score was used to measure liver function in these patients. The primary study end point was 30-day mortality in patients presenting with liver dysfunction. Secondary study end point was liver enzymes after TAVR. RESULTS: The mean Model for End-Stage Liver Disease score in patients with chronic liver disease was 16.8 ± 6.2 (median, 18; range, 7 to 26). The 30-day mortality was 9.1% (57 of 629) in patients presenting without liver disease and 9.1% (1 of 11) in patients with liver disease (p = 1.00). Patients with chronic liver disease showed significantly higher preoperative levels of γ-glutamyl transpeptidase (p < 0.001). After TAVR, we observed a significant increase in alanine aminotransferase on postoperative day 3 compared with preoperative values (p < 0.001), accompanied by a decrease in albumin (p < 0.001). CONCLUSIONS: Liver cirrhosis per se is not considered as a contraindication for cardiac operations. In the present study, we did not observe a higher 30-day mortality rate in liver cirrhotic patients undergoing TAVR, suggesting TAVR as a feasible alternative with acceptable outcomes in patients with chronic liver disease. Moreover, the present study is the first to evaluate liver variables in patients undergoing TAVR.
引用
- Wendt D, Kahlert P, Canbay A, et al. Impact of Liver Indicators on Clinical Outcome in Patients Undergoing Transcatheter Aortic Valve Implantation. Ann Thorac Surg. 2017. PMID: 28577851. doi:10.1016/j.athoracsur.2017.02.075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。